Latest filings (excl ownership)
DEF 14A
Definitive proxy
11 Apr 24
ARS
2023 FY
Annual report to shareholders
11 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Esperion Announces Proposed Public Offering of Common Stock
22 Jan 24
424B5
Prospectus supplement for primary offering
22 Jan 24
8-K
Regulation FD Disclosure
18 Jan 24
424B5
Prospectus supplement for primary offering
18 Jan 24
8-K
Results of Operations and Financial Condition
11 Jan 24
8-K
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
3 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Esperion Reports Third Quarter 2023 Financial Results
7 Nov 23
S-8
Registration of securities for employees
24 Aug 23
S-8
Registration of securities for employees
1 Aug 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
8-K
Esperion Reports Second Quarter 2023 Financial Results
1 Aug 23
8-K
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
26 Jun 23
8-K
Departure of Directors or Certain Officers
15 Jun 23
DEFA14A
Additional proxy soliciting materials
25 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Esperion Reports First Quarter 2023 Financial Results
9 May 23
8-K
Other Events
4 May 23
DEF 14A
Definitive proxy
13 Apr 23
ARS
2022 FY
Annual report to shareholders
13 Apr 23
PRE 14A
Preliminary proxy
3 Apr 23
8-K
Other Events
27 Mar 23
8-K
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
22 Mar 23
424B3
Prospectus supplement
22 Mar 23
424B5
Prospectus supplement for primary offering
21 Mar 23
8-K
Other Events
15 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin
6 Mar 23
424B5
Prospectus supplement for primary offering
21 Feb 23
10-K
2022 FY
Annual report
21 Feb 23
8-K
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
21 Feb 23
8-K
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
9 Jan 23
8-K
Entry into a Material Definitive Agreement
23 Nov 22
8-K
Esperion Appoints Ben Halladay Chief Financial Officer
16 Nov 22
10-Q
2022 Q3
Quarterly report
1 Nov 22
8-K
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
1 Nov 22
Latest ownership filings
4
Eric Warren
15 Mar 24
4
Joanne M. Foody
15 Mar 24
4
Benjamin Looker
15 Mar 24
4
Benjamin Halladay
15 Mar 24
4
Sheldon L. Koenig
15 Mar 24
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G/A
Two Seas Capital LP
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
WASATCH ADVISORS LP
9 Feb 24
SC 13G/A
BB BIOTECH AG
24 Jan 24
SC 13G/A
BB BIOTECH AG
24 Jan 24
SC 13G/A
MILLENNIUM MANAGEMENT LLC
17 Jan 24
SC 13G/A
Meditor Group Ltd
3 Jan 24
SC 13G
Two Seas Capital LP
5 Oct 23
4
Eric Warren
21 Sep 23
144
Notice of proposed sale of securities
20 Sep 23
SC 13G
MILLENNIUM MANAGEMENT LLC
29 Aug 23
SC 13G
MILLENNIUM MANAGEMENT LLC
28 Aug 23
4
Eric Warren
21 Aug 23
144
Notice of proposed sale of securities
18 Aug 23
4
Joanne M. Foody
9 Aug 23
4
Eric Warren
20 Jul 23
144
Notice of proposed sale of securities
19 Jul 23
4
Eric Warren
22 Jun 23
144
Notice of proposed sale of securities
21 Jun 23
4
Alan Fuhrman
16 Jun 23
4
Tracy M Woody
16 Jun 23
4
Seth H. Z. Fischer
16 Jun 23
4
J MARTIN CARROLL
16 Jun 23
4
NICOLE VITULLO
16 Jun 23
4
Jay Shepard
16 Jun 23
4
STEPHEN ROCAMBOLI
16 Jun 23
4
ANTONIO M JR MD D PHIL GOTTO
16 Jun 23
SC 13G/A
BlackRock Inc.
8 Jun 23
4
Eric Warren
18 May 23
144
Notice of proposed sale of securities
17 May 23
4
J MARTIN CARROLL
11 May 23
4
STEPHEN ROCAMBOLI
11 May 23